Skip to main content
SpringerLink
Log in

Atopic Dermatitis

  • Chapter
  • First Online:
Severe Skin Diseases in Children

  • 1083 Accesses

Abstract

A small proportion of children with atopic dermatitis continue to have considerable disease despite multiple attempts to optimize topical and adjunctive treatments for epidermal barrier repair and control of the associated inflammation and itch. Systemic agents may be appropriate for such cases, but their use does require careful thought and discussion of short- and long-term benefits versus risks. Currently available agents are reviewed here, along with additional considerations before and during therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACD:

Allergic contact dermatitis

AD:

Atopic dermatitis

HSTCL:

Hepatosplenic T-cell lymphoma

IVIg:

Intravenous immunoglobulin

MED:

Minimal erythema dose

MM:

Mycophenolate mofetil

PUVA:

Psoralen with ultraviolet A

TPMT:

Thiopurine methyltransferase

References

  1. Carroll CL, Balkrishnan R, Feldman SR, Fleischer Jr AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–9.

    Article  PubMed  Google Scholar 

  2. Grundmann SA, Beissert S. Modern aspects of phototherapy for atopic dermatitis. J Allergy (Cairo). 2012;2012:121797.

    Google Scholar 

  3. Walker D, Jacobe H. Phototherapy in the age of biologics. Semin Cutan Med Surg. 2011;30(4):190–8.

    Article  PubMed  CAS  Google Scholar 

  4. Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed. 2007;23(4):106–12.

    Article  PubMed  Google Scholar 

  5. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, Altmeyer P, Kreuter A. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160(3):652–8.

    Article  PubMed  CAS  Google Scholar 

  6. Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V, Knol EF, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60(1):77–84.

    Article  PubMed  Google Scholar 

  7. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28–33.

    PubMed  CAS  Google Scholar 

  8. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. 2011;25(6):727–9.

    Article  PubMed  CAS  Google Scholar 

  9. Tan E, Lim D, Rademaker M. Narrowband UVB phototherapy in children: a New Zealand experience. Australas J Dermatol. 2010;51(4):268–73.

    Article  PubMed  Google Scholar 

  10. Trueb RM. Therapies for childhood psoriasis. Curr Probl Dermatol. 2009;38:137–59.

    PubMed  Google Scholar 

  11. Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment option. Semin Cutan Med Surg. 2010;29(2):115–20.

    Article  PubMed  CAS  Google Scholar 

  12. Dabade TS, Davis DM, Wetter DA, Hand JL, McEvoy MT, Pittelkow MR, el-Azhary RA, Davis MD. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100–6.

    Article  PubMed  CAS  Google Scholar 

  13. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4):812–24.

    Article  PubMed  Google Scholar 

  14. Jacob SE, Yang A, Herro E, Zhang C. Contact allergens in a pediatric population: association with atopic dermatitis and comparison with other North American referral centers. J Clin Aesthet Dermatol. 2010;3(10):29–35.

    PubMed  Google Scholar 

  15. Kwan JM, Jacob SE. Contact dermatitis in the atopic child. Pediatr Ann. 2012;41(10):422–8.

    Article  PubMed  Google Scholar 

  16. Beattie PE, Green C, Lowe G, Lewis-Jones MS. Which children should we patch test? Clin Exp Dermatol. 2007;32(1):6–11.

    PubMed  CAS  Google Scholar 

  17. Giordano-Labadie F, Rance’ F, Pellegrin F, Bazex J, Dutau G, Scharze HP. Frequency of contact allergy in children with atopic dermatitis: results of a prospective study of 137 cases. Contact Dermatitis. 1999;40(4):192–5.

    Article  PubMed  CAS  Google Scholar 

  18. Jacob SE, Burk CJ, Connelly EA. Patch testing: another steroid-sparing agent to consider in children. Pediatr Dermatol. 2008;25(1):81–7.

    Article  PubMed  Google Scholar 

  19. Abramovits W, Perlmutter A. Steroids versus other immune modulators in the management of allergic dermatoses. Curr Opin Allergy Clin Immunol. 2006;6(5):345–54.

    Article  PubMed  CAS  Google Scholar 

  20. Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;120(3):e527–34.

    Article  PubMed  Google Scholar 

  21. La Rosa M, Musarra I, Ranno C, Maiello N, Negri L, Del Giudice Jr MM, et al. A randomized, double-blind, placebo controlled crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Therap Res. 1995;56:720–6.

    Article  Google Scholar 

  22. Heddle RJ, Soothill JF, Bulpitt CJ, Atherton DJ. Combined oral and nasal beclomethasone dipropionate in children with atopic eczema: a randomised controlled trial. Br Med J (Clin Res Ed). 1984;289(6446):651–4.

    Article  CAS  Google Scholar 

  23. Galli E, Chini L, Moschese V, Paone F, Menichelli A, Fraioli G, Rossi P. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr. 1994;83(3):315–7.

    Article  PubMed  CAS  Google Scholar 

  24. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol. 2000;25(7):559–66.

    Article  PubMed  CAS  Google Scholar 

  25. Forte WC, Sumita JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr). 2005;33(6):307–11.

    Article  Google Scholar 

  26. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–19.

    PubMed  CAS  Google Scholar 

  27. Metz BJ. Highlights of the Society for Pediatric Dermatology Annual Meeting, July 12-15 2007, Chicago, Illinois. Conference report. Medscape Dermatology 2007 [online]. Available from http://www.medscape.com/viewarticle/562439. Accessed 27 Dec 2012.

    Google Scholar 

  28. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142: 52–8.

    Article  PubMed  CAS  Google Scholar 

  29. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55:369–89.

    Article  PubMed  Google Scholar 

  30. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711–34.

    Article  PubMed  CAS  Google Scholar 

  31. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308–15.

    Article  PubMed  CAS  Google Scholar 

  32. Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol. 2003;20:531–4.

    Article  PubMed  Google Scholar 

  33. Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689–94.

    Article  PubMed  Google Scholar 

  34. Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1): 29–35.

    Article  PubMed  CAS  Google Scholar 

  35. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157(1):127–32.

    Article  PubMed  CAS  Google Scholar 

  36. El Kabbaj D, Hassani M, Kadiri M, Mounach J, Ouhabi H, Haimeur C, Oualim Z. Mycophenolate mofetil associated with progressive multifocal leukoencephalopathy with successful outcome. Saudi J Kidney Dis Transpl. 2012;23(4):790–3.

    Article  PubMed  Google Scholar 

  37. Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2012;21(11):1216–20.

    Article  PubMed  CAS  Google Scholar 

  38. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96.

    Article  PubMed  Google Scholar 

  39. Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol. 2012;53(1):1–18.

    Article  PubMed  Google Scholar 

  40. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol. 2007;56(4):686–90.

    Article  PubMed  Google Scholar 

  41. Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol. 2005;52(2):316–40.

    Article  PubMed  Google Scholar 

  42. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–9.

    Article  PubMed  CAS  Google Scholar 

  43. Rouse C, Siegfried E. Methotrexate for atopic dermatitis in children. J Am Acad Dermatol. 2008;58 Suppl 2:AB7.

    Google Scholar 

  44. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351–6.

    Article  PubMed  CAS  Google Scholar 

  45. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol. 2002;27(1):3–7.

    Article  PubMed  CAS  Google Scholar 

  46. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69(3):297–306.

    Article  PubMed  CAS  Google Scholar 

  47. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res. 2011;3(2):89–95.

    Article  PubMed  CAS  Google Scholar 

  48. Turner PJ, Kakakios A, Wong LC, Wong M, Campbell DE. Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol. 2012;29(2):177–81.

    Article  PubMed  Google Scholar 

  49. Panahi Y, Davoudi SM, Madanchi N, Abolhasani E. Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis. Clin Exp Med. 2012;12(4):241–5.

    Article  PubMed  CAS  Google Scholar 

  50. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993;28(2 Pt 1):189–97.

    Article  PubMed  CAS  Google Scholar 

  51. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol. 1998;134(7):799–804.

    Article  PubMed  CAS  Google Scholar 

  52. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, Kim TY. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol. 2000;42(6):1033–40.

    Article  PubMed  CAS  Google Scholar 

  53. Leung DY, Gao PS, Grigoryev DN, Rafaels NM, Streib JE, Howell MD, Taylor PA, Boguniewicz M, Canniff J, Armstrong B, Zaccaro DJ, Schneider LC, Hata TR, Hanifin JM, Beck LA, Weinberg A, Barnes KC. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. J Allergy Clin Immunol. 2011;127(4):965–73.e1-5.

    Article  PubMed  CAS  Google Scholar 

  54. Frisch S, Siegfried EC. The clinical spectrum and therapeutic challenge of eczema herpeticum. Pediatr Dermatol. 2011;28(1):46–52.

    Article  PubMed  Google Scholar 

  55. Bremmer MS, Bremmer SF, Baig-Lewis S, Simpson EL. Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions. J Am Acad Dermatol. 2009;61(4):666–76.

    Article  PubMed  CAS  Google Scholar 

  56. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52(3 Pt 1):522–6.

    Article  PubMed  Google Scholar 

  57. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30(11):2506–7.

    PubMed  Google Scholar 

  58. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol. 2004;114(1):150–8.

    Article  PubMed  Google Scholar 

  59. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5): 496–500.

    Article  PubMed  CAS  Google Scholar 

  60. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–8.

    PubMed  Google Scholar 

  61. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–6.

    Article  PubMed  CAS  Google Scholar 

  62. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121(1): 122–8.

    Article  PubMed  CAS  Google Scholar 

  63. Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol. 2011;128(5):1128–30.

    Article  PubMed  CAS  Google Scholar 

  64. Keaney TC, Bhutani T, Sivanesan P, Bandow GD, Weinstein SB, Cheung LC, Malick F, Koo J. Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. J Am Acad Dermatol. 2012;67(4): 636–41.

    Article  PubMed  CAS  Google Scholar 

  65. Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, Marks I, Cherill R, Emady-Azar S, Paul C, Multicentre Investigator Group. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol. 2005;152(6): 1296–303.

    Article  PubMed  CAS  Google Scholar 

  66. Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol. 2008;144(1):84–8.

    Article  PubMed  CAS  Google Scholar 

  67. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–7.

    Article  PubMed  CAS  Google Scholar 

  68. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26(8):1705–14.

    PubMed  CAS  Google Scholar 

  69. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–17.

    Article  PubMed  Google Scholar 

  70. O’Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9(3):364–9.

    Article  PubMed  Google Scholar 

  71. Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V. Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009;26(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  72. Homsi S, Alexandrescu DT, Milojkovic N, Abouzgheib W, Bachour K, Homsi Y, Dasanu CA. Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate. Dermatol Online J. 2010;16(5):1.

    PubMed  Google Scholar 

  73. Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036–43.

    Article  PubMed  CAS  Google Scholar 

  74. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4(5):511–22.

    Article  PubMed  Google Scholar 

  75. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1.

    Article  PubMed  CAS  Google Scholar 

  76. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009;20(6):1080–5.

    Article  PubMed  CAS  Google Scholar 

  77. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011;23(12): 1150–6.

    Article  PubMed  CAS  Google Scholar 

  78. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009;87(6):785–94.

    Article  PubMed  CAS  Google Scholar 

  79. Eisen HJ, Kowabashiga J, Keogh A, Bourge R, Renlund D, Mentzer R, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24(5): 517–25.

    Article  PubMed  Google Scholar 

  80. ClinicalTrials.gov, study NCT01447381 at http://clinicaltrials.gov. Accessed 3 Jan 2013.

Download references

Author information

Authors and Affiliations

  1. Alamance Dermatology, 1638 Memorial Drive, Burlington, NC, 27215, USA

    David A. Dasher MD

  2. Depatments of Pediatrics and Medicine (Dermatology), University of California, San Diego and Rady Children’s Hospital, San Diego, 8010 Frost Street, Suite 602, San Diego, CA, 92123, USA

    Wynnis L. Tom MD

Authors
  1. David A. Dasher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wynnis L. Tom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wynnis L. Tom MD .

Editor information

Editors and Affiliations

  1. Pediatric & Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA

    Wynnis L. Tom

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dasher, D.A., Tom, W.L. (2014). Atopic Dermatitis. In: Tom, W. (eds) Severe Skin Diseases in Children. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39532-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39532-1_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39531-4

  • Online ISBN: 978-3-642-39532-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation